-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gilead Sciences recently announced that the U.
Although effective treatment options available to pregnant women infected with HIV reduce the possibility of transmission of HIV infection during the perinatal period, pediatric HIV remains a global health problem
The FDA approved Biktarvy for HIV-1 infection in children weighing at least 14 kg, based on data from cohort 3 of the Phase 2/3 open-label single-arm study (NCT02881320)
Biktarvy is a single-tablet regimen (STR) taken orally once a day for the treatment of HIV-1 infection
In the United States, Biktarvy was approved for marketing in February 2018.
In China, Biktarvy was approved in Hong Kong in October 2018 and approved in the Mainland in August 2019
Note: The original text has been deleted
Original source: US Food and Drug Administration Approves Expanded Indication of Gilead's Biktarvy® for Treatment of HIV-1 in Pediatric Populations